Advertisement

What We Know About the ‘Cicada’ COVID Variant Now

Popular Posts

Advertisement
Digital rendering of viral spike protein

Quick Read

  • The BA.3.2 ‘Cicada’ variant has been identified in 22 countries, including the U.S. and Japan.
  • The strain features a high mutation count of 70 to 75, primarily affecting the spike protein.
  • Clinical data shows no increase in disease severity compared to previous strains, though sore throat is a common symptom.

Health authorities worldwide are intensifying surveillance of the BA.3.2 COVID-19 variant, informally dubbed “Cicada,” following its confirmed detection across 22 nations, including the United States, Japan, and the United Kingdom. First identified in South Africa in late 2024, the variant has moved from a dormant presence in genomic databases to a steady, observable increase in cases throughout early 2026, prompting the U.S. Centers for Disease Control and Prevention (CDC) to classify it as a strain of interest.

Advertisement

Understanding the Cicada Variant’s Genetic Profile

The “Cicada” moniker refers to the virus’s long period of low-level circulation before its recent emergence in routine monitoring. According to expert analysis, the BA.3.2 strain possesses between 70 and 75 mutations, a significantly higher count than previous iterations such as JN.1. These mutations are concentrated in the spike protein, which is the primary mechanism the virus uses to enter human cells. Virologists are particularly focused on these specific changes, as they suggest an enhanced ability to bypass immunity gained from both prior infections and existing vaccination protocols.

Monitoring Global Spread and Public Health Risks

While the variant is currently present in over 20 countries, health officials emphasize that it has not yet become the dominant global strain. Detection efforts have been bolstered by wastewater surveillance, which has allowed researchers to track the variant’s footprint even in areas where clinical testing rates have declined. Despite the high number of mutations, current clinical data indicates that the severity of illness associated with BA.3.2 remains consistent with previous variants, with most cases presenting as mild to moderate.

Managing Symptoms and Vaccination Strategy

Patients infected with the Cicada variant typically report standard COVID-19 symptoms, including fever, persistent cough, fatigue, and muscle pain. A notable clinical observation, however, is an increased frequency of severe sore throat among those diagnosed with this specific strain. Public health guidelines remain focused on the necessity of staying up-to-date with vaccinations, which medical experts maintain are the most effective defense against hospitalization and severe outcomes, even in the face of breakthrough infections caused by newer mutations.

While the emergence of the BA.3.2 variant underscores the ongoing evolution of the virus, current data suggests that the primary challenge lies in the strain’s potential for immune evasion rather than a shift toward higher clinical severity or mortality.

LATEST NEWS

Advertisement